Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Curate Biosciences

Explore full profile

Transforming the process of purifying and enriching cells for cell therapy production

Carlsbad, United StatesFounded 2012Biotech & Life Sciences
Valuation $100–250M Last recorded · 2020
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Curate Biosciences and the history behind them.

About Curate Biosciences

Curate Biosciences, formerly known as GPB Scientific, is a life sciences company focused on transforming cell therapy manufacturing. Founded in 2002, with dedicated work on its primary system beginning in 2016, the company operates with facilities in Carlsbad, California. The name change from GPB Scientific, which stood for 'getting people better,' to Curate Biosciences was a strategic move to better reflect the company's core mission of providing high-quality cells for therapeutic use.

The company was founded by Mike Grisham, who also serves as Chairman. Initially, the firm and its spinoffs developed various devices for the microfluidics field, with an early focus on prenatal diagnostics. The pivot towards cell and gene therapy capitalizes on this deep experience. The business targets biopharmaceutical companies, contract manufacturers (CDMOs), and academic research centers involved in developing cell therapies like CAR-T. Its business model centers on selling its proprietary cell processing system and the associated single-use cartridges required for its operation.

The flagship product is the Curate® Cell Processing System, a benchtop instrument that automates cell separation. It utilizes a proprietary microfluidic technology called Deterministic Cell Separation™ (DCS), which gently sorts cells based on size. This method is exceptionally efficient, recovering about 90% of white blood cells from a patient's blood product while eliminating over 90% of red blood cells and 99% of platelets. The key benefit is the delivery of a cleaner, larger, and healthier quantity of starting cells, a critical bottleneck in manufacturing gene and cell therapies. By improving the quality of this initial material, the system can reduce the overall cost of autologous cell therapy production by up to 50% and shorten the time needed to create a patient-specific dose. The system is designed for ease of use, processing a standard blood cell unit in approximately 45 minutes with minimal hands-on time.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2012
Headquarters
Carlsbad, United States
Employees
3
Open positions
None listed
Dealroom signal
65.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCEquity / VC May 2021 $18M $72M Amgenbd · Vensana Capital —
LATE VC✓Equity / VC Apr 2020 $26M $102M Vensana Capital · Amgen Ventures ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Curate Biosciences website traffic

Latest recorded traffic for Curate Biosciences is 200 monthly website visits, up 17.6% over the last three months. Curate Biosciences's team grew 0% over the past year.

Latest monthly visits200 3-month web change+17.6% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later3 investors entered at this stage

  • Vensana Capital
  • Amgen Ventures
  • Amgenbd

Other known investors2 additional known investors

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Carlsbad HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Curate Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Curate Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.